After selecting Cambridge as the home base for its first U.S startup accelerator, Intel is ready to kick off its first iteration of the Intel Ignite program.
Santa Clara chipmaker Intel Corp. (Nasdaq: INTC) announced Wednesday the startups that will take part in the first Boston's installment of its Intel Ignite program. The accelerator, which kicks off Wednesday as well, is slated to last 12 weeks.
Intel said that the Boston cohort emerged among 18 companies that were shortlisted from a group of 60 that went through a due diligence process. Overall, over 500 prospects were received for Boston. Average funding for each selected company is more than $8.5 million in seed or pre-seed capital.
Intel announced last month the expansion of Intel Ignite into Boston, joining existing programs in Tel Aviv and Munich that have graduated about 90 startups since 2019. During the Boston program, companies will meet with Intel and industry mentors, attend sales and marketing workshops, and receive help with product-market fit, culture and team building.
"Each of the startups selected for the Boston cohort is unique and disruptive," said Mark Castleman, managing director for Intel Ignite Boston, in a statement. "From quantum to AI to nano, these startups are building and innovating for the future, and they are pushing the envelope of what it means to create impact in deep tech."
Here are the 10 companies that were selected for the inaugural Boston program (descriptions provided):
Atlantic Quantum Corp.
Builds quantum computers with scalable control architecture.
Control Plane Corporation
Sky computing solution that allows developers to run workloads on all clouds with combined power and benefits of all providers.
Einblick
Enables data scientists to explore data, build predictive models and deploy data apps in concert with stakeholders.
Geminus.ai
An industrial AI platform as a service (PaaS) that fuses measurement data and physics to power efficient digital twins.
Hellometer
Tracks customers’ dining experience to decrease service time.
Irradiant
Ultrafast nanoscale 3D printing of metals, semiconductors, and dielectrics to create the future of optics and photonics.
LASE Innovation
Develops laser particles as novel optical barcodes, focusing on advancing single-cell analysis for life sciences.
Modzy
Provides MLOps software platform to integrate, run, and monitor ML/AI models anywhere, from the enterprise to the edge.
Normal Computing Corporation
Building a full-stack thermodynamic AI platform.
Revela
Uses biological models and AI to develop novel consumer health solutions.
LabCentral 238
LabCentral is a network of co-working spaces specifically designed for biotech companies.
Gary Higgins / Boston Business Journal
LabCentral's newest site, LabCentral 238, is a 100,000-square-foot facility at 238 Main St. in Kendall Square.
Gary Higgins / Boston Business Journal
The new site is meant to house biotechs that are in their "teenage" phase.
Gary Higgins / Boston Business Journal
LabCentral 238 is within walking distance from its sister sites at 700 Main St. and 610 Main St., which are designed for smaller startups.
Gary Higgins / Boston Business Journal
LabCentral 238 has been a work in progress for the last year.
Gary Higgins / Boston Business Journal
The site held a "soft opening" last November and began bringing in new startups.
Gary Higgins / Boston Business Journal
This August, it unveiled the second phase of construction, opening a new floor and increasing its capacity to about 14 companies.
Gary Higgins / Boston Business Journal
A view of the Longfellow Bridge and Boston from the windows of LabCentral 238.
Gary Higgins / Boston Business Journal
LabCentral 238 finally held its grand opening earlier this month.
Gary Higgins / Boston Business Journal
The new facility boasts 13 private lab suites for companies of up to 50 employees each.
Gary Higgins / Boston Business Journal
Each suite can hold up to 33 benches with fume hoods, centrifuges, refrigerators and freezers.
Gary Higgins / Boston Business Journal
There is also a shared bioanalytical lab featuring plate readers, microscopes and qPCR machines.
Gary Higgins / Boston Business Journal
Other shared spaces include a shared analytical chemistry lab with high-performance liquid chromatography and mass specttometry capabilities.
Gary Higgins / Boston Business Journal
LabCentral 238 has shared bioprocessing equipment like bioreactors and filtration equipment.
Gary Higgins / Boston Business Journal
In order to claim space at LabCentral 238, startups must pay anywhere from a couple hundred to $135,000, depending on their needs.
Gary Higgins / Boston Business Journal
LabCentral is known for its strict vetting process.
Gary Higgins / Boston Business Journal
Only about one-fifth of companies that apply are admitted.
Gary Higgins / Boston Business Journal
LabCentral's admissions team also asks company leaders how they plan to contribute to LabCentral as a community, not simply a worksite.
Gary Higgins / Boston Business Journal
LabCentral co-founder and president Johannes Fruehauf says he wants startups' employees to be "citizens of the space."
Gary Higgins / Boston Business Journal
A private, non-profit institution, LabCentral was founded in 2013 as a launchpad for high potential life-sciences and biotech startups.
Gary Higgins / Boston Business Journal
More than 184 researchers, technicians, scientists and entrepreneurs from 11 companies work out of LabCentral 238 today.
Gary Higgins / Boston Business Journal
Asimov, Codagenix, Kernal Biologics, Mediar Therapeutics, NextPoint Therapeutics, Nvelop Therapeutics, Satellite Bio, Seismic Therapeutic, Tevard Biosciences, TreeFrog Therapeutics and Vedere all work out of the facility.
Gary Higgins / Boston Business Journal
In the heart of Kendall Square, LabCentral 238 enjoys close proximity to major university research centers, hospitals, biotech and pharmaceutical companies.
Gary Higgins / Boston Business Journal
LabCentral 238 is designed to support the transition from R&D bench-scale science into scalable production of pre-clinical material in anticipation of biomanufacturing.
Gary Higgins / Boston Business Journal
Astellas is LabCentral 238's founding sponsor.
Gary Higgins / Boston Business Journal
The site is particularly focused on companies developing complex therapeutics, including cell and gene therapies, which are notoriously tricky to manufacture at scale.
Gary Higgins / Boston Business Journal
LabCentral 238 has kitchen and open-plan communal space designed to facilitate interaction and collaboration.
Gary Higgins / Boston Business Journal
The site offers two-year service agreements, with the potential for a one-year extension.
Gary Higgins / Boston Business Journal
If a company wishes to terminate its agreement, it must provide six months' notice.
Gary Higgins / Boston Business Journal
